Diagnosis and management of dementia with Lewy bodies
Ian Grant McKeith, Dennis W. Dickson, James S Lowe, Murat Emre, John Tiernan O'Brien, Howard Feldman, Jeffrey L. Cummings, John E. Duda, Carol Frances Lippa, Elaine K. Perry, Dag Aarsland, Heii Arai, Clive G. Ballard, Bradley F. Boeve, David John Burn, Durval C. Costa, Teodoro del Ser, Bruno Dubois, Douglas R Galasko, Serge G. Gauthier, Christopher G. Goetz, Estrella Gómez‐Tortosa, Glenda Margaret Halliday, Lawrence A. Hansen, John Hardy, Takeshi Iwatsubo, Raj N. Kalaria, Daniel Kaufer, Rose Anne Kenny, Amos D. Korczyn, Kenji Kosaka, V. M.-Y. Lee, Andrew John Lees, Irene Litvan, Elisabet Londos, Oscar L. López, Satoshi Minoshima, Y Mizuno, J. A. Molina, Elizabeta B. Mukaetova‐Ladinska, Florence Pasquier, Robert H. Perry, Jörg Bernhard Schulz, John Q. Trojanowski, Masahito Yamada
Neurology · 2005 · 5,143 citations
Abstract
The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. REM sleep behavior disorder, severe neuroleptic sensitivity, and reduced striatal dopamine transporter activity on functional neuroimaging are given greater diagnostic weighting as features suggestive of a DLB diagnosis. The 1-year rule distinguishing between DLB and Parkinson disease with dementia may be difficult to apply in clinical settings and in such cases the term most appropriate to each individual patient should be used. Generic terms such as Lewy body (LB) disease are often helpful. The authors propose a new scheme for the pathologic assessment of LBs and Lewy neurites (LN) using alpha-synuclein immunohistochemistry and semiquantitative grading of lesion density, with the pattern of regional involvement being more important than total LB count. The new criteria take into account both Lewy-related and Alzheimer disease (AD)-type pathology to allocate a probability that these are associated with the clinical DLB syndrome. Finally, the authors suggest patient management guidelines including the need for accurate diagnosis, a target symptom approach, and use of appropriate outcome measures. There is limited evidence about specific interventions but available data suggest only a partial response of motor symptoms to levodopa: severe sensitivity to typical and atypical antipsychotics in approximately 50%, and improvements in attention, visual hallucinations, and sleep disorders with cholinesterase inhibitors.
Cite this paper
McKeith, I. G., Dickson, D. W., Lowe, J. S., Emre, M., O’Brien, J. T., Feldman, H., Cummings, J. L., Duda, J. E., Lippa, C. F., Perry, E. K., Aarsland, D., Arai, H., Ballard, C. G., Boeve, B. F., Burn, D. J., Costa, D. C., Ser, T. del, Dubois, B., Galasko, D. R., … Yamada, M. (2005). Diagnosis and management of dementia with lewy bodies. Neurology, 65(12), 1863–1872. https://doi.org/10.1212/01.wnl.0000187889.17253.b1
Read it with every claim anchored
Add this paper to a project, ask questions of it, and get answers that point to the exact passage.
Start freeRelated papers
- Clinical diagnosis of Alzheimer's disease1984
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment2005
- Special Care Units and Traditional Care in Dementia: Relationship with Behavior, Cognition, Functional Status and Quality of Life - A Review2013
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease2011
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease2018
Metadata from OpenAlex (CC0). Citations are generated from the published record.